FDA Approves First Gene Therapy To Restore Hearing In Congenital Deafness
The Food and Drug Administration on Thursday approved the first gene therapy designed to restore hearing in people born deaf in the United States, the agency said.
The treatment targets congenital deafness tied to a specific genetic fault and is delivered as a one-time therapy meant to repair key cells in the inner ear. The approval clears the therapy for use under the agency's terms and opens the way for patient access.
The decision follows years of laboratory research and human clinical trials that tested safety and whether patients regained measurable hearing. This is the first time the FDA has cleared a gene-based therapy aimed at reversing a sensory loss rather than treating a disease like cancer or a metabolic disorder.
Doctors and patient groups said the move could transform care for people with inherited deafness, while regulators will monitor long-term safety and effectiveness. Questions about who will qualify, how much insurers will cover, and broad access remain unresolved.
đ Key Facts
- FDA approved the first gene therapy for hearing loss on April 23, 2026, targeting congenital deafness caused by mutations in the OTOF gene.
- The Regeneron therapy uses adeno-associated viruses surgically infused into the inner ear to deliver a working otoferlin gene split into two parts.
- Clinical data from 20 treated patients showed restored hearing in children who had been profoundly deaf from birth, prompting FDA authorization.
- Regeneron plans to make the therapy available in the U.S. within weeks and says it will initially be offered free to eligible patients.
đ° Source Timeline (1)
Follow how coverage of this story developed over time